NC
UTHR icon

nVerses Capital’s United Therapeutics UTHR Stock Holding History

nVerses Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$35.8K – 856
2024
Q3 		$35.8K Sell
100
-800
-89% -$270K 0.02% 712
2024
Q2 		$287K Buy
+900
New +$238K 0.17% 193

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

nVerses Capital's UTHR Position: Q4 2024 in Review

nVerses Capital sold out of United Therapeutics (UTHR) in Q4 2024, closing a stake of 100 shares — an estimated $35.8K sold.

nVerses Capital first reported a position in UTHR in Q2 2024 and held it in 2 quarters. The position peaked at $287K in Q2 2024. 672 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

  • nVerses Capital reported no remaining United Therapeutics position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 100 United Therapeutics shares in Q4 2024, an estimated $35.8K.
  • nVerses Capital first reported a position in United Therapeutics in Q2 2024 and held it in 2 quarters.
  • nVerses Capital's United Therapeutics position peaked at $287K in Q2 2024.
  • 672 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.